Study: GAL-001: Adaptive Phase II in Refractory Melanoma
Phase II
· Site: Mount Halifax Oncology Center (Dr. A. Reyes)
· consented 2026-05-26
Adverse events
0
Serious AEs
0
Open data queries
0
Luna dropout signal
+0.25
Adverse events
No adverse events recorded.
Data queries
No data queries.
☾ Luna engagement
Messages
2
Escalations
2
Check-ins
2
Mood ø
2.0
Med adherence · 7d
14%
Last check-in
2026-08-18
📅 Next appointment: Cycle 3 infusion — NXC-101
on 2026-08-23